4 EV Charging Stocks To Watch Ahead Of July 2022
If you’re an investor looking to gain some exposure to the electric vehicle (EV) industry in the stock market, investing in EV charging stocks could…
Investor
COVID-19 Vaccine Stocks: Is Inovio Still In Play?
When it comes to psychedelics, today’s article notes that “While this industry is still in its early stages, the promising pInovio Pharmaceuticals went from being…
2 Former Wall Street Pros Share Their 5 Innovative Stocks To Buy
At the recent Global Financial Summit, two former Wall Street professionals shared their picks for innovative stocks to buy for the opportunity to profit from…
When It Comes To These 2 Biopharma Stocks’ Near-Term Gains, Analysts Are Seeing (More Than) Double!
Today’s article highlights two clinical-stage biopharmaceutical stocks that analysts expect to more than double in the coming months — one engaged in discovering and developing…
These 19 “Moaty” Small-Caps Are High-Quality & Undervalued
Smaller-cap companies have had a good 12 months, and the author of today’s article notes that “the return picture over the trailing three-year period suggests…
Will August Bring FDA Approvals For These Biotech Stocks?
With just a few days remaining in July, the FDA has approved four novel drugs this month, including a treatment for a parasitic “sleeping sickness”…
Why Synthetic Biology Could Be An Internet-Level Investment Opportunity – And How To Play It
“This is what it might have been like 25 years ago if some guy had walked up to you and said the internet was going…
Biotech Buys: 2 Top Picks Under $10
As a result of the pandemic, investors have likely become familiar with a number of biotech names over the past year and a half that…
A Speculative Stock For What May Be “The Next Big Thing To Sweep Through Biotech”
The company discussed in today’s article is a potential leader in a burgeoning field that the author declares “has the potential to revolutionize medicine in…
While Biotech Underperformed In The First Half Of 2021, These Names Stood Out With Solid Gains
While biotech stocks underperformed the broader market in the first half of the year, some names – particularly those focused on neurodegenerative diseases and cancer…